Teva

HERZUMA

Manufacturer:

Teva

Herzuma HCPCS:

Q5113

HCPCS Code Descriptor:

Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg

Category:

Q Code

Herzuma NDCs:

63459-0305-47, 63459-0303-43

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Herzuma:

HERZUMA is an Oncology Biosimilar drug manufactured by Teva and administered via the Intravenous route of administration. The Q Code: Q5113 is aligned to the drug HERZUMA.

Herzuma (trastuzumab) is used to treat specific types of breast and stomach cancers by targeting the HER2 protein in cancer cells. Herzuma can be used in combination with other cancer medications. This medication is manufactured by Cephalon and is biosimilar to the medication Herceptin (J9356). Herzuma has been aligned to the Q Code Q5113 since July 2019. Patient assistance programs for this medication can be found through Truxima.

ACCESS PRICING AND MORE BY REGISTERING

Q5113 Added Date:

July 1, 2019

Q5113 Effective Date:

July 1, 2019

Q5113 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Herzuma billing and coding information.
Herzuma patient assistance information can be found through Teva Support Solutions at the URL: https://www.truximahcp.com/support-resources
HERZUMA prescribing information can be found at the link below:
Information regarding HERZUMA’s side effects can be found at MedlinePlus